23 May 2024
An exciting milestone in our pursuit to make CAR T-cell therapy a standard of care in New Zealand, the Environmental Protection Authority NZ has approved use of chimeric antigen receptor (CAR) T-cells in our phase 2 clinical trial with BioOra.
As a trial of this kind had never been done before in New Zealand, our team has put significant time and effort into working with national regulatory bodies such as the EPA and MedSafe to navigate and establish the necessary regulatory pathways to bring CAR T-cell technology to New Zealand.
In doing so, we have opened doors for similar life-saving cell therapy trials to be undertaken here in the future - whether our own or others.
Related articles
A revolution in cancer care is near; here’s what’s needed to make it happen
9 May 2024
Read more
Significant milestone reached in first NZ CAR T-cell trial as preparations made for larger phase 2 registration trial
25 March 2024
Read more
Freemasons New Zealand renews support for CAR T-cell therapy
10 November 2023
Read more
RNZ: Engineering immune cells to kill cancer
5 November 2023
Read more
Trial results offer hope to Kiwis with incurable blood cancer
3 November 2023
Read more
BioOra appoints CAR T-cell therapy pioneer, Professor Carl June to Board
31 October 2023
Read more